Experimental combo targets Hard-to-Treat tumors
NCT ID NCT03589339
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called NBTXR3, which is activated by radiation, together with an immunotherapy (anti-PD-1) in people with advanced cancers that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 145 participants with various cancer types, including head and neck, lung, and liver cancers, are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Christus St. Vincent Regional Cancer Center
Santa Fe, New Mexico, 87505, United States
-
Emory University
Atlanta, Georgia, 30308, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Henry Ford Cancer Institute
Detroit, Michigan, 48202, United States
-
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwell Health
Manhasset, New York, 11030, United States
-
Sanford Cancer Center
Sioux Falls, South Dakota, 57104, United States
-
St Luke's University Health Network
Bethlehem, Pennsylvania, 18015, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of North Carolina, School of Medicine
Chapel Hill, North Carolina, 27516, United States
Conditions
Explore the condition pages connected to this study.